Xocova®
Xocova® (or Ensitrelvir) is an antiviral drug for COVID-19 that has already been approved under the emergency regulatory approval system in Japan. Ensitrelvir suppresses the replication of SARS-CoV-2 by selectively inhibiting 3CL protease. It is the first antiviral drug to show both clinical symptomatic efficacy for five typical Omicron-related symptoms and antiviral efficacy in patients with a mild to moderate SARS-CoV-2 infection.
Pre-clinical
Phase 1
Phase 2
Phase 3
Regulatory
Suppresses the replication of SARS-CoV-2 by selectively inhibiting 3CL protease
TISSUEGENE-C (TG-C)
TG-C is a non-surgical treatment cell-mediated gene therapy for osteoarthritis, which is the most common form of arthritis. A first-in-class cell and gene therapy, TG-C targets knee osteoarthritis through a single intra-articular injection.
Pre-clinical
Phase 1
Phase 2
Phase 3
Regulatory
Grade 3 knee osteoarthritis
LEDAGA®
LEDAGA® (chlormethine) gel is an alkylating drug indicated for the topical treatment of MF-CTCL in adult patients. LEDAGA® is a gel which is applied topically once a day. The drug has been approved by the European Commission (for the treatment of MF-CTCL in adult patients). Since June 2019, LEDAGA® is commercialized in more than 30 countries including Europe, Canada, Latin America.
Pre-clinical
Phase 1
Phase 2
Phase 3
Regulatory
Topical treatment of MF-CTCL
Anamorelin
ANAMORELIN is a novel once-daily, orally active ghrelin receptor agonist indicated for the treatment of cancer cachexia in patients suffering from malignant tumors of non-small cell lung cancer (NSCLC), gastric cancer, pancreatic cancer or colorectal cancer. Cancer cachexia is a complex metabolic disorder syndrome, characterized by decreased body weight (especially decreased muscle mass) and anorexia associated with cancer. It has been well documented that cancer cachexia causes a significant impact on patients’ quality of life (QOL) and prognosis.